Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N
Department of Internal Medicine Diabetes Unit, Civic Hospital, Bentivoglio, Bologna, Italy.
J Int Med Res. 1997 Mar-Apr;25(2):81-6. doi: 10.1177/030006059702500204.
The aim was to investigate sulodexide as a possible therapeutic tool for treating micro- and macroalbuminuria in diabetic patients. Fifteen patients (13 micro- and 2 macroalbuminuric) with Type II diabetes, were treated with 600 lipoprotein-lipase releasing units of sulodexide by the intramuscular route, daily for 28 days, and followed up for 2 months. The main evaluation parameter was the albumin excretion rate. At the end of treatment, six of the 13 microalbuminuric patients showed a decrease in the albumin excretion rate, which increased again in three of the six during follow-up. In the two macroalbuminuric patients the albumin excretion rate decreased at the end of treatment and remained unchanged after a further 2 months. Overall analysis (15 patients) showed a significant decrease (P < 0.05) in the albumin excretion rate compared with baseline. Metabolic control and blood pressure remained unchanged during the entire period of study. No adverse events were registered. It is concluded that sulodexide administration has a favourable effect in reducing the albumin excretion rate in Type II diabetic patients with micro- and macroalbuminuria.
目的是研究舒洛地昔作为治疗糖尿病患者微量和大量白蛋白尿的一种可能治疗手段。15例2型糖尿病患者（13例微量白蛋白尿患者和2例大量白蛋白尿患者）接受了600脂蛋白脂肪酶释放单位的舒洛地昔肌肉注射治疗，每日1次，共28天，并随访2个月。主要评估参数是白蛋白排泄率。治疗结束时，13例微量白蛋白尿患者中有6例白蛋白排泄率下降，其中3例在随访期间白蛋白排泄率再次升高。2例大量白蛋白尿患者治疗结束时白蛋白排泄率下降，再过2个月后保持不变。总体分析（15例患者）显示，与基线相比，白蛋白排泄率显著降低（P<0.05）。在整个研究期间，代谢控制和血压保持不变。未记录到不良事件。得出结论，舒洛地昔给药对降低2型糖尿病合并微量和大量白蛋白尿患者的白蛋白排泄率有良好效果。
